Liberate Bio
Private Company
Total funding raised: $5M
Overview
Liberate Bio is a private, preclinical-stage biotech founded in 2021 and based in San Diego, CA. The company is pioneering a novel delivery platform, RAPTOR™, to enable in vivo genetic medicines for diseases driven by cells outside the liver, with an initial focus on hematologic cancers and autoimmune disorders. Backed by Khosla Ventures and led by a team with deep expertise in delivery and genetic medicine, Liberate has demonstrated proof-of-concept in non-human primates and is advancing its first pipeline programs. Its business model is therapeutics-focused, aiming to develop and commercialize its own drug candidates.
Technology Platform
RAPTOR™ platform: a scalable discovery system that uses in vivo screening to identify lipid nanoparticle (LNP) formulations capable of delivering genetic payloads to specific cell populations outside the liver, particularly in the bone marrow and immune system (myeloid lineage).
Funding History
1Opportunities
Risk Factors
Competitive Landscape
Liberate Bio competes in the crowded field of next-generation drug delivery, facing companies like ReCode Therapeutics, GenEdit, and Arbutus Biopharma, as well as large biopharma with internal efforts. Its specific focus on in vivo generation of engineered immune cells (like CAR-M) also places it in competition with cell therapy companies and those developing in vivo gene editing (e.g., Intellia Therapeutics) for similar indications.